Shandong Boan Biotechnology Co (FRA:UJ9) Other Current Liabilities: €16.19 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UJ9 Shandong Boan Biotechnology Co Ltd FRA:UJ9
44 GF Score
Price €0.53
GF Value €1.75
! 5 Warning Signs
View Full Analysis

What is Shandong Boan Biotechnology Co Other Current Liabilities?

Shandong Boan Biotechnology Co FRA:UJ9 -1.87% 44 Other Current Liabilities is €16.19 Mil as of Dec. 2025. GuruFocus rates FRA:UJ9 with a GF Score™ of 44/100 and a GF Value™ of €1.75. The stock has 5 warning signs investors should review.

Shandong Boan Biotechnology Co's other current liabilities for the quarter that ended in Dec. 2025 was €16.19 Mil.

Shandong Boan Biotechnology Co's quarterly other current liabilities declined from Dec. 2024 (€12.41 Mil) to Jun. 2025 (€-0.00 Mil) but then increased from Jun. 2025 (€-0.00 Mil) to Dec. 2025 (€16.19 Mil).

Shandong Boan Biotechnology Co's annual other current liabilities declined from Dec. 2023 (€23.14 Mil) to Dec. 2024 (€12.41 Mil) but then increased from Dec. 2024 (€12.41 Mil) to Dec. 2025 (€16.19 Mil).

Shandong Boan Biotechnology Co Other Current Liabilities Related Terms

Shandong Boan Biotechnology Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Shandong Boan Biotechnology Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Boan Biotechnology Co Other Current Liabilities Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 9.12 24.01 23.14 12.41 16.19

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 23.14 0.00 12.41 -0.00 16.19
FRA:UJ9
44GF Score
Shandong Boan Biotechnology Co Ltd FRA:UJ9
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Boan Biotechnology Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €16.19 Mil mean?
Shandong Boan Biotechnology Co (FRA:UJ9) has a Other Current Liabilities of €16.19 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Shandong Boan Biotechnology Co.
Is Shandong Boan Biotechnology Co's Other Current Liabilities too high?
Shandong Boan Biotechnology Co's current Other Current Liabilities is €16.19 Mil. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's Other Current Liabilities compare to VRTX and REGN?
Shandong Boan Biotechnology Co's Other Current Liabilities of €16.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Shandong Boan Biotechnology Co. Shandong Boan Biotechnology Co's current Other Current Liabilities is €16.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current Other Current Liabilities of €16.19 Mil. The stock's GF Value™ is €1.75, compared to a current price of €0.53 — trading 70% below its estimated fair value. The current Other Current Liabilities is €16.19 Mil. Shandong Boan Biotechnology Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current Other Current Liabilities is €16.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued. The current stock price of €0.53 is trading 70% below its estimated GF Value™ of €1.75.

Key valuation signals for FRA:UJ9:

  • Other Current Liabilities: €16.19 Mil
  • GF Value™: €1.75 vs. price of €0.53 (70% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shandong Boan Biotechnology Co Business Description

Other Exchanges 06955:Hong Kong
Address No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score

Get the complete analysis for FRA:UJ9

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price
€1.75
GF Value